(0.17%) 5 255.00 points
(0.09%) 39 679 points
(0.27%) 18 304 points
(0.32%) $78.51
(0.71%) $2.27
(-1.16%) $2 347.40
(-0.63%) $28.33
(-0.06%) $1 006.60
(-0.07%) $0.928
(0.15%) $10.85
(-0.07%) $0.798
(-1.35%) $91.42
Live Chart Being Loaded With Signals
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay...
Stats | |
---|---|
Today's Volume | 20 895.00 |
Average Volume | 61 896.00 |
Market Cap | 20.00M |
EPS | $-1.810 ( 2024-03-26 ) |
Next earnings date | ( $-1.670 ) 2024-05-21 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.230 |
ATR14 | $0.0380 (1.79%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-22 | Baxter Timothy E | Buy | 65 000 | Common stock |
2024-02-22 | White Debra | Buy | 65 000 | Common stock |
2024-02-22 | Sparks Ronald M | Buy | 65 000 | Common stock |
2024-02-22 | Harvey Joan B | Buy | 65 000 | Common stock |
2024-02-22 | Glennon Michael J | Buy | 65 000 | Common stock |
INSIDER POWER |
---|
99.95 |
Last 94 transactions |
Buy: 11 877 994 | Sell: 5 035 719 |
PAVmed Inc Correlation
10 Most Positive Correlations | |
---|---|
KSPN | 0.908 |
ALTO | 0.907 |
ASTS | 0.904 |
TCDA | 0.904 |
AEHR | 0.903 |
TUSK | 0.899 |
VTNR | 0.896 |
ODT | 0.892 |
TSLA | 0.892 |
VRAY | 0.886 |
10 Most Negative Correlations | |
---|---|
MRTX | -0.907 |
SUMO | -0.905 |
DSEY | -0.905 |
TAST | -0.9 |
STAY | -0.888 |
CCRC | -0.887 |
ATVI | -0.883 |
HCCI | -0.882 |
SFBC | -0.882 |
ARNA | -0.877 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
PAVmed Inc Financials
Annual | 2023 |
Revenue: | $2.45M |
Gross Profit: | $-6.90M (-281.40 %) |
EPS: | $-8.87 |
FY | 2023 |
Revenue: | $2.45M |
Gross Profit: | $-6.90M (-281.40 %) |
EPS: | $-8.87 |
FY | 2022 |
Revenue: | $377 000 |
Gross Profit: | $-3.24M (-858.62 %) |
EPS: | $-17.06 |
FY | 2021 |
Revenue: | $500 000 |
Gross Profit: | $-85 000.00 (-17.00 %) |
EPS: | $-1.070 |
Financial Reports:
No articles found.
PAVmed Inc
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators